Welcome to the Men's Health Knowledge Centre
As a disease topic Men's Health covers a broad set of issues affecting men of all ages. Some of the issues requiring greater focus and more thorough dissemination of information amongst the healthcare community, are those that have the potential to go undetected in the early stages. These include, hypogonadism and erectile dysfunction.
Early detection and more regular health checks of these diseases, not only improve prognosis and efficacy of treatment outcomes, but also quality of life.
- February 2014 - Testosterone treatment in obese hypogonadal men with type 2 diabetes
- Treatment with testosterone undecanoate (TU) 1,000 mg was followed for up to 6 years, the longest follow-up period to date.
- In total, 156 obese (BMI ≥30 kg/m2) hypogonadal men with T2DM and dyslipidemia, aged between 41–73 years, were investigated
- TU significantly and progressively improved anthropometric parameters of obesity over 6 years
- Waist circumference (p<0.0001), actual body weight (p=0.001), percentage body weight change (p<0.0001), and BMI (p<0.0001) were improved over 6 years compared with baseline and each year compared to previous year
- TU progressively and significantly decreased levels of HbA1c by a mean of 1.93 ± 0.06% over 6 years (p<0.0001) and each year compared to previous year
- Measures of BP, lipid profiles, liver enzymes, and levels of inflammatory biomarkers were significantly improved after 6 years
- Mean improvements in systolic (23.15 ± 0.83 mmHg) and diastolic (15.07 ± 0.8 mmHg) BP reached a level of statistical significance (p<0.0001) at 3 years, and were sustained for 6 years
- Improvements in HDL-C (+35.03 ± 5.11%), total cholesterol (–32.12 ± 1.41%), LDL-C (–25.93 ± 1.63%), triglycerides (–29.91 ± 2%), liver enzymes aspartate transaminase (12.01 ± 1.33 U/L) and alanine transaminase (12.46 ± 1.83 U/L), and the inflammatory marker C-reactive protein (2.88 ± 0.28 U/L) were gradual and significant (all p<0.0001)